Karyopharm Therapeutics (NASDAQ:KPTI) Cut to Hold at ValuEngine

ValuEngine downgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a buy rating to a hold rating in a research note issued to investors on Thursday, ValuEngine reports.

A number of other brokerages also recently weighed in on KPTI. Robert W. Baird reissued an outperform rating and issued a $25.00 price target (up from $15.00) on shares of Karyopharm Therapeutics in a report on Friday, July 5th. Wedbush set a $11.00 price target on shares of Sangamo Therapeutics and gave the company a hold rating in a report on Monday, July 8th. BidaskClub raised shares of Zumiez from a sell rating to a hold rating in a report on Saturday, June 22nd. Zacks Investment Research downgraded shares of ExlService from a hold rating to a sell rating in a report on Wednesday. Finally, HC Wainwright reissued a buy rating and issued a $48.00 price target (down from $52.00) on shares of CELYAD SA/ADR in a report on Friday, July 5th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of $17.41.

NASDAQ:KPTI opened at $8.03 on Thursday. Karyopharm Therapeutics has a 1 year low of $3.92 and a 1 year high of $21.71. The firm has a fifty day moving average price of $6.37. The company has a current ratio of 6.19, a quick ratio of 6.19 and a debt-to-equity ratio of 0.98.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Thursday, May 9th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.25). Karyopharm Therapeutics had a negative net margin of 1,005.85% and a negative return on equity of 119.66%. The firm had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.75 million. Research analysts forecast that Karyopharm Therapeutics will post -3.79 EPS for the current year.

Large investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. lifted its holdings in shares of Karyopharm Therapeutics by 660.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,800 shares of the company’s stock worth $36,000 after acquiring an additional 3,300 shares during the period. Legal & General Group Plc lifted its holdings in shares of Karyopharm Therapeutics by 31.3% during the 4th quarter. Legal & General Group Plc now owns 10,116 shares of the company’s stock worth $95,000 after acquiring an additional 2,411 shares during the period. BNP Paribas Arbitrage SA lifted its holdings in shares of Karyopharm Therapeutics by 169,300.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 10,164 shares of the company’s stock worth $59,000 after acquiring an additional 10,158 shares during the period. Metropolitan Life Insurance Co. NY lifted its holdings in shares of Karyopharm Therapeutics by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 16,275 shares of the company’s stock worth $152,000 after acquiring an additional 12,711 shares during the period. Finally, DekaBank Deutsche Girozentrale lifted its holdings in shares of Karyopharm Therapeutics by 20.7% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 19,800 shares of the company’s stock worth $419,000 after acquiring an additional 3,400 shares during the period. 84.20% of the stock is owned by institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.

Featured Article: What impact do institutional investors have on markets?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.